APLS
APLS
NASDAQ · Biotechnology

Apellis Pharmaceuticals Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$41.03
+0.02 (+0.05%)
As of May 9, 1:25 AM ET ·
APLS News2 articles
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Markets
Biogen to Acquire Apellis in $5.6B Deal, Adding Rare Disease Portfolio
Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.
Markets